|
|
|
| Study on the Effects of Different Treatments on Heart Rate Variability Serum KLK1 and TIMP-1 Levels and Short-Term Prognosis in Patients with Coronary Artery Disease |
| XIE Xiaoli, et al |
| 986 Hospital of PLA Air Force, Shaanxi Xi'an 710000, China |
|
|
|
|
Abstract Objective: To investigate the effects of domestic rapamycin drug-eluting stent and paclitaxel drug-eluting balloon on heart rate variability, levels of serum Kallikrein 1 (KLK1) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) and short-term prognosis in patients with coronary heart disease. Methods: The data of 105 patients with coronary artery disease who received percutaneous coronary intervention in the hospital from November 2019 to May 2021 were reviewed, and they were divided into the observation group (56 cases, using domestic rapamycin drug-eluting stent) and the control group (49 cases, treated with domestic paclitaxel drug-eluting balloon) according to different stents used. The heart rate variability-related indicators [standard deviation of normal sinus RR interval within 5 min (SDNN), standard deviation of the 5-minute average RR intervals (SDANN), percent of differences between adjacent NN intervals greater than 50 ms (pNN50)] before surgery, at 1 week after surgery and at 1 year follow-up, levels of KLK1, TIMP-1, endothelin-1 (ET-1) and nitric oxide (NO) before surgery and at 1 week after surgery as well as short-term prognosis [vascular re-stenosis, vascular re-thrombosis, major adverse cardiovascular events (MACE)] at 1 year of follow-up were compared between the two groups. Results: There were statistical differences in the SDNN, SDANN and pNN50 in repeated measures analysis of variance between the two groups form the aspect of time-point effect (P<0.017), and the above three indicators showed upward trends with the prolongation of postoperative time. The absolute values of differences of serum KLK1, TIMP-1, NO and plasma ET-1 before and after surgery revealed statistically significant differences between the two groups (P<0.05), and the changes in the observation group were greater than those in the control group. At 1 year of follow-up, the incidence rate of vascular re-stenosis in the observation group was lower than that in the control group (P<0.05), but there were no statistically significant differences in the incidence rates of vascular re-thrombosis and MACE between the two groups (P>0.05). Conclusion: Domestic rapamycin drug-eluting stent can effectively regulate heart rate variability in patients with coronary artery disease, and it has a positive effect on improving serum KLK1 and TIMP-1 levels, and can help protect and repair the endothelial function, reduce the risk of stent stenosis, and achieve the good short-term prognosis.
|
|
|
|
|
|
[1] 王永霞,朱斌.麝香保心丸联合地尔硫卓治疗老年冠心病稳定型心绞痛的临床疗效[J].成都医学院学报,2020,15(3):373-375.
[2] Shin D,Dai N,Lee SH,et al.Physiological distribution and local severity of coronary artery disease and outcomes after percutaneous coronary intervention[J].JACC Cardiovasc Interv,2021,14(16):1771-1785.
[3] Ullrich H,Olschewski M,Münzel T,et al.Coronary in-stent restenosis:predictors and treatment[J].Dtsch Arztebl Int,2021,118(38):637-644.
[4] 杨峰,赵骞,张世轩,等.雷帕霉素联合CD133抗体支架预防血管再狭窄的有效性和安全性[J].中国组织工程研究,2022,26(4):579-584.
[5] 中华医学会心血管病学分会介入心脏病学组,中国医师协会心血管内科医师分会血栓防治专业委员会,中华心血管病杂志编辑委员会.中国经皮冠状动脉介入治疗指南(2016)[J].中华心血管病杂志,2016,44(5):382-400.
[6] 徐晶,白净,崔倩卫,等.血清miR-647PTEN与ACS患者PCI术后支架内再狭窄的关系[J].河北医学,2022,28(4):639-644.
[7] 杨文节,乔锐,张宜春,等.血管内超声联合雷帕霉素洗脱支架在冠心病合并糖尿病患者中的治疗效果[J].中国循证心血管医学杂志,2020,12(7):882-885.
[8] Pan C,Han Y,Lu J.Structural design of vascular stents:a review[J].Micromachines (Basel),2021,12(7):770.
[9] 冀晓冲,管琳,李文一,等.心率变异性临床应用研究进展[J].中西医结合心脑血管病杂志,2020,18(17):2809-2811.
[10] 殷雪娇,李慧,梁荣珍,等.血清sTWEAK、KLK1水平预测老年急性非ST段抬高型心肌梗死病人急诊PCI预后的研究[J].实用老年医学,2022,36(4):364-368.
[11] Ben Braiek A,Chahed H,Dumont F,et al.Identification of biomarker panels as predictors of severity in coronary artery disease[J].Cell Mol Med,2021,25(3):1518-1530. |
|
|
|
2023, Vol. 29 
